{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T08:40:20Z","timestamp":1710664820771},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.biologicals.2009.09.004","type":"journal-article","created":{"date-parts":[[2009,10,25]],"date-time":"2009-10-25T08:19:56Z","timestamp":1256458796000},"page":"158-161","source":"Crossref","is-referenced-by-count":3,"title":["Removal of TSE agents by depth or membrane filtration from plasma products"],"prefix":"10.1016","volume":"38","author":[{"given":"Peter L.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauran","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2009.09.004_bib1","first-page":"55","article-title":"Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie and BSE of cattle","volume":"75","author":"Prusner","year":"1991","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.biologicals.2009.09.004_bib2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrmicro1025","article-title":"The state of the prion","volume":"2","author":"Weissmann","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.biologicals.2009.09.004_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt\u2013Jacob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review Study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2009.09.004_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy","volume":"9","author":"Foster","year":"1999","journal-title":"Transfus Med"},{"issue":"Suppl.","key":"10.1016\/j.biologicals.2009.09.004_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1741-6892.2004.00444.x","article-title":"Removal of TSE agents from blood products","volume":"87","author":"Foster","year":"2004","journal-title":"Vox Sang"},{"issue":"Suppl. 5","key":"10.1016\/j.biologicals.2009.09.004_bib6","first-page":"32","article-title":"Creutzfeldt\u2013Jakob disease: reflections on the risk from blood product therapy","volume":"13","author":"Brown","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2009.09.004_bib7","doi-asserted-by":"crossref","unstructured":"Taylor DM. Resistance of transmissible spongiform encephalopathy agents to decontamination. Prions: a challenge for science, medicine and the public health system. 2004; 11:136\u201345.","DOI":"10.1159\/000077054"},{"key":"10.1016\/j.biologicals.2009.09.004_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/BA20060249","article-title":"Comparative studies on the thermostability of five strains of transmissible spongiform-encephalopathy agent","volume":"27","author":"Fernie","year":"2007","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.biologicals.2009.09.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1000206","article-title":"Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation","volume":"4","author":"Giles","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.biologicals.2009.09.004_bib10","first-page":"3","article-title":"Application of virus filters to biological products: practical and regulatory considerations","volume":"5","author":"Roberts","year":"2000","journal-title":"Eur J Parenter Sci"},{"key":"10.1016\/j.biologicals.2009.09.004_bib11","first-page":"72","article-title":"An overview of viral filtration in biopharmaceutical manufacturing","volume":"7","author":"Carter","year":"2002","journal-title":"Eur J Parenter Sci"},{"key":"10.1016\/j.biologicals.2009.09.004_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2009.09.004_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0021-9975(71)90100-9","article-title":"An experimental examination of the scrapie agent in the cell membrane mixtures. II The association of scrapie activity with membrane fractions","volume":"81","author":"Millson","year":"1971","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.biologicals.2009.09.004_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5360\/membrane.18.357","article-title":"Removal of causative agent of Creutzfieldt\u2013Jakob disease (CJD) through membrane filtration method","volume":"18","author":"Tateishi","year":"1993","journal-title":"Membrane"},{"key":"10.1016\/j.biologicals.2009.09.004_bib15","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1128\/JVI.61.12.3688-3693.1987","article-title":"Mouse polyclonal and monoclonal antibody to scrapie associated fibril protein","volume":"61","author":"Kascsak","year":"1987","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2009.09.004_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biologicals.2007.04.005","article-title":"Prion removal by nanofiltration under different experimental conditions","volume":"36","author":"Yunoki","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2009.09.004_bib17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1046\/j.1537-2995.2002.00160.x","article-title":"Removal of prion challenge from an immune globulin preparation by the use of a size-exclusion filter","volume":"42","author":"Van Holten","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2009.09.004_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/biol.1996.0013","article-title":"Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol\u00ae","volume":"24","author":"Golker","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2009.09.004_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biologicals.2005.11.007","article-title":"CJD PrP removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobobuline\u00ae)","volume":"34","author":"Truchot","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2009.09.004_bib20","first-page":"217","article-title":"Validation of a prion and virus purification process in the manufacture of bovine thrombin","volume":"7","author":"Terraba","year":"2007","journal-title":"J Appl Res"},{"key":"10.1016\/j.biologicals.2009.09.004_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","article-title":"Monitoring plasma processing steps with a sensitive western blot assay for the detection of the prion protein","volume":"84","author":"Lee","year":"2000","journal-title":"J Virol Methods"},{"key":"10.1016\/j.biologicals.2009.09.004_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1423-0410.2003.00312.x","article-title":"Evaluation of depth filtration to remove prion challenge from an immune globulin preparation","volume":"85","author":"Van Holten","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2009.09.004_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/biol.2002.0327","article-title":"Purity of spiking agent affects partitioning of prions in plasma protein purification","volume":"30","author":"Vey","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2009.09.004_bib24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","article-title":"Large scale production of human plasma fractions","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105609001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105609001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T08:14:55Z","timestamp":1710663295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105609001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1045105609001286"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2009.09.004","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}